Research Advisory Council
Toby Ferguson, MD, PhD
Chief Medical Officer, Voyager Therapeutics
Dr. Ferguson is a neuromuscular neurologist and neuroscientist focused on developing treatments for neuromuscular diseases. He is currently the Chief Medical Officer for Voyager Therapeutics, a biotechnology company developing gene therapies for neurological diseases. Before Voyager, he was Head of the Neuromuscular Development Unit at Biogen, leading the neuromuscular clinical development group driving preclinical strategy within neurodegenerative and neuromuscular diseases. His group also worked closely with the scientific, biomarker and commercial teams at Biogen, Ionis and other external collaborators to identify novel disease targets and to develop the needed tools for efficient clinical development. Dr. Ferguson has advanced multiple programs into the clinic for ALS, SMA, Myotonic Dystrophy and Parkinson’s disease. Prior to Biogen, he had a clinical neuromuscular neurology practice and a lab focused on peripheral axon injury and regeneration at Shriners Research Center and Temple University in Philadelphia. Dr. Ferguson trained in neurology and neuromuscular neurology at the University of Pennsylvania and earned an MD and PhD (Neuroscience) from the University of Florida.
Amanda Haidet-Phillips, Ph.D
Executive Director, Global Program Team Leader, Sarepta Therapeutics
Dr. Haidet-Phillips leads cross-functional program teams at Sarepta Therapeutics to bring genetic medicines from the laboratory to patients with rare, neuromuscular diseases. She has led programs spanning from IND- to BLA-enabling stages with focus across the muscular dystrophies. Prior to Sarepta, Dr. Haidet-Phillips worked in biotech and pharma sectors as part of AveXis and Novartis Institute for BioMedical Research to lead the transition of gene therapy products from the pre-clinical proof of concept stage in R&D to first-in human trials.
Prior to joining industry, Dr. Haidet-Phillips served as Scientific Portfolio Director for the Muscular Dystrophy Association where she led the strategic direction of research investments for motor and peripheral nerve diseases. Dr. Haidet-Phillips completed a post-doctoral fellowship at Johns Hopkins University and she received a Ph.D from The Ohio State University.
Kleopas Kleopa, MD, PhD, FAAN, FEAN
Professor and Senior Neurologist, Cyprus Institute of Neurology and Genetics
Dr. Kleopa is a Professor and Senior Neurologist at the Cyprus Institute of Neurology and Genetics and the head of the Neuroscience Department and Coordinator of the Center for Neuromuscular Disorders, delivering cutting edge diagnostic and therapeutic services to patients with neuromuscular and rare neurological disorders. His research focuses on understanding neurological disease mechanisms and the development of innovative cell-targeted gene therapies for inherited neuropathies and leukodystrophies. Results of his research are currently being developed for clinical translation in collaboration with industry. Dr. Kleopa is an elected Board Member of the International Charcot-Marie-Tooth and Related Disorders Consortium. He also serves as a Member of the Scientific Advisory Boards of the USA CMT Association and the Gilbert Foundation Neurofibromatosis-1 Gene Therapy Initiative. Dr. Kleopa earned his MD and PhD at the University of Wuerzburg, Germany.
William Motley, MD, PhD
Senior Director of Clinical Development and Program Lead, Rapport Therapeutics
Dr. Motley is currently Senior Director of Clinical Development and Program Lead at Rapport Therapeutics, a precision neuroscience company, and worked as a consultant to the company’s founding team at Boston-based Third Rock Ventures. Previously he served as Director of Translational Medicine for Flare Therapeutics and was a Senior Associate at Third Rock Ventures where he was a member of Flare’s founding team and worked on diverse aspects of company creation. Dr. Motley also serves as a member of the Medical and Scientific Advisory Board of Palvella Therapeutics, a company focused on bringing therapies to patients with rare dermatologic diseases with no approved therapies. A member of CMTRF’s Board of Directors since 2023, he holds an MD from the University of Pennsylvania, a Doctorate in Neurogenetics from the University of Oxford (UK), and a BA in Biochemistry from Middlebury College. He completed a neurology residency at the Johns Hopkins University School of Medicine. His doctoral and post-doctoral research experiences focused on identifying new causes of CMT and characterizing pathological mechanisms of the disease.
Charlotte Sumner, MD
Professor of Neurology and Neuroscience, Johns Hopkins University School of Medicine
Dr. Sumner co-directs the Johns Hopkins Muscular Dystrophy Association Care Center, the Spinal Muscular Atrophy, and the Charcot-Marie-Tooth clinics, which deliver multi-disciplinary clinical care, engage in international natural history studies, and provide cutting-edge therapeutics. Her practice is notable for its focus on individuals with inherited neuromuscular disorders of peripheral nerves and motor neurons, including spinal muscular atrophy and CMT. Her research focuses on developing treatments for degenerative disorders of motor neurons and peripheral nerves. Notably, Dr. Sumner was a previous member of the SAB, and her recommendations played a pivotal role in steering the foundation towards addressing delivery challenges.

